Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Sudan: Conflict, cancer care, and ripple effects on the region

Dr Nazik Hammad - University of Toronto, Toronto, Canada
Sudan: Conflict, cancer care, and ripple effects on the region ( Dr Nazik Hammad - University of Toronto, Toronto, Canada )
19 Jul 2023

Geriatric oncology in resource-limited settings

Dr Enrique Soto Perez de Celis - National Institute of Medical Sciences, Mexico City, Mexico
Geriatric oncology in resource-limited settings ( Dr Enrique Soto Perez de Celis - National Institute of Medical Sciences, Mexico City, Mexico )
18 Jul 2023

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )
6 Jul 2023

Hormonal Therapy and Complications

Dr Gerardo Barrantes - Hospital Mexico, Costa Rica
Hormonal Therapy and Complications ( Dr Gerardo Barrantes - Hospital Mexico, Costa Rica )
28 Jun 2023

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )
19 Jun 2023

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy

Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA
ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy ( Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA )
19 Jun 2023

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )
19 Jun 2023

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )
15 Jun 2023

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg
ASCO 2023: Latest in PARP inhibitors in prostate cancer ( Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg )
6 Jun 2023

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands
CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2023

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )
6 Jun 2023

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )
5 Jun 2023